Apyx Medical Corp. Hits New 52-Week High of $4.65

Apyx Medical Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 4.65 on June 5, 2026. This achievement marks a remarkable increase of 179.37% over the past year, significantly outperforming the S&P 500, which has seen a gain of 24.32% during the same period. The company's market capitalization stands at USD 152 million, reflecting its position within the microcap category. Despite its recent price surge, Apyx Medical Corp. continues to operate at a loss, as indicated by its P/E ratio, which remains unavailable. The company has a debt-to-equity ratio of 0.24, suggesting a relatively low level of debt compared to equity. However, its return on equity is notably negative at -76.38%, and the price-to-book ratio is reported at 10.47. Overall, Apyx Medical Corp.'s recent performance highlights its notable growth trajectory within the competitive landscape of the pharmaceuticals and biotechnology industry.